Beyond The Pandemic, An Interview With Astellas’ Percival Barretto-Ko
Executive Summary
Astellas Pharma US accounts for roughly one-third of the parent company’s annual revenues with a growing focus on immuno-oncology. The unit’s president discusses lessons from the pandemic, racial disparities in health care and business development.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Astellas Pays $300m+ For iota In ‘Pharma-Plus’ Push
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.
Virus-Hit Astellas Cuts Forecast
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.